Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AbbVie Signs Deal With Synlogic

by Ann M. Thayer
February 15, 2016 | A version of this story appeared in Volume 94, Issue 7

AbbVie and Synlogic will collaborate and use Synlogic’s combined microbiome and synthetic biology approach for drug development. The partners have picked inflammatory bowel conditions, including Crohn’s disease and ulcerative colitis, as the first targets for probiotic therapies. Cambridge, Mass.-based Synlogic engineers probiotic bacteria with genetic switches to modulate metabolic functions in the microbiome. Under a multiyear deal, it will discover, characterize, and optimize synthetic-biotics-based candidates for evaluation and clinical testing by AbbVie.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.